Exelixis Inc. mostly lost its bid to exclude two MSN Laboratories Private Ltd. expert opinions that three patents for the blockbuster cancer drug Cabometyx, which accounted for nearly three-quarters of Exelixis’ 2021 revenue, should be invalidated because they’re obvious.
Judge Richard G. Andrews granted Exelixis’ motion only as to 12 paragraphs of one expert’s opening report on two of the patents, according to a Wednesday order in the U.S. District Court for the District of Delaware. Andrews’ corresponding opinion is under seal. A three-day bench trial is scheduled to start May 16 in Wilmington.
The segment Andrews blocked refers to ...
